Free Trial

Aclarion (ACON) Competitors

Aclarion logo
$7.61 -0.14 (-1.81%)
Closing price 04:00 PM Eastern
Extended Trading
$7.56 -0.06 (-0.72%)
As of 06:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ACON vs. ENZ, BRTX, MGRX, SSY, BGLC, VSEE, ATIP, DHAC, OTRK, and NIVF

Should you be buying Aclarion stock or one of its competitors? The main competitors of Aclarion include Enzo Biochem (ENZ), Biorestorative Therapies (BRTX), Mangoceuticals (MGRX), SunLink Health Systems (SSY), BioNexus Gene Lab (BGLC), VSee Health (VSEE), ATI Physical Therapy (ATIP), Digital Health Acquisition (DHAC), Ontrak (OTRK), and NewGenIvf Group (NIVF). These companies are all part of the "healthcare" industry.

Aclarion vs. Its Competitors

Enzo Biochem (NYSE:ENZ) and Aclarion (NASDAQ:ACON) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

Enzo Biochem has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, Aclarion has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500.

In the previous week, Aclarion had 2 more articles in the media than Enzo Biochem. MarketBeat recorded 2 mentions for Aclarion and 0 mentions for Enzo Biochem. Aclarion's average media sentiment score of 0.20 beat Enzo Biochem's score of 0.00 indicating that Aclarion is being referred to more favorably in the news media.

Company Overall Sentiment
Enzo Biochem Neutral
Aclarion Neutral

Enzo Biochem has a net margin of -75.34% compared to Aclarion's net margin of -12,227.10%. Enzo Biochem's return on equity of -7.96% beat Aclarion's return on equity.

Company Net Margins Return on Equity Return on Assets
Enzo Biochem-75.34% -7.96% -5.49%
Aclarion -12,227.10%-126.89%-106.61%

36.9% of Enzo Biochem shares are held by institutional investors. Comparatively, 7.5% of Aclarion shares are held by institutional investors. 11.4% of Enzo Biochem shares are held by insiders. Comparatively, 0.8% of Aclarion shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Aclarion has a consensus price target of $11,758.50, indicating a potential upside of 154,413.80%. Given Aclarion's stronger consensus rating and higher probable upside, analysts plainly believe Aclarion is more favorable than Enzo Biochem.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enzo Biochem
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Aclarion
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Aclarion has lower revenue, but higher earnings than Enzo Biochem.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enzo Biochem$29.09M0.59-$26.08MN/AN/A
Aclarion$54.60K81.12-$6.99MN/AN/A

Summary

Aclarion beats Enzo Biochem on 7 of the 13 factors compared between the two stocks.

Get Aclarion News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACON and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACON vs. The Competition

MetricAclarionMedical Services IndustryMedical SectorNASDAQ Exchange
Market Cap$4.43M$7.19B$5.46B$8.92B
Dividend YieldN/A2.78%5.24%4.04%
P/E RatioN/A27.3327.0120.12
Price / Sales81.1233.47380.1493.34
Price / CashN/A20.3926.2128.59
Price / Book0.156.727.995.57
Net Income-$6.99M$230.16M$3.16B$248.40M
7 Day PerformanceN/A1.27%3.69%6.04%
1 Month Performance10.77%2.35%2.90%7.69%
1 Year Performance-99.71%46.16%34.30%20.97%

Aclarion Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ACON
Aclarion
2.1982 of 5 stars
$7.61
-1.8%
$11,758.50
+154,413.8%
-99.7%$4.43M$54.60K0.007News Coverage
ENZ
Enzo Biochem
N/A$0.33
-14.8%
N/A-69.3%$17.03M$29.09M0.00520Gap Down
High Trading Volume
BRTX
Biorestorative Therapies
2.7638 of 5 stars
$1.67
+3.5%
$18.00
+980.7%
-18.7%$12.49M$400K-1.137Gap Up
MGRX
Mangoceuticals
0.8461 of 5 stars
$1.52
-12.1%
N/A-97.9%$7.86M$620K-0.333News Coverage
Positive News
Gap Down
SSY
SunLink Health Systems
0.9756 of 5 stars
$0.88
+0.6%
N/A+27.5%$6.20M$31.09M6.291,376News Coverage
Positive News
BGLC
BioNexus Gene Lab
0.4155 of 5 stars
$3.07
+10.8%
N/A+27.8%$5.53M$9.51M0.0030
VSEE
VSee Health
1.199 of 5 stars
$1.16
+5.5%
$5.00
+331.0%
N/A$4.18MN/A0.00N/AGap Up
ATIP
ATI Physical Therapy
N/A$0.90
+4.7%
N/A-79.4%$3.97M$741.86M-0.055,600Gap Up
DHAC
Digital Health Acquisition
N/A$1.10
-3.5%
N/A-86.8%$3.96MN/A0.002,021News Coverage
Gap Down
OTRK
Ontrak
2.8999 of 5 stars
$0.50
-9.8%
$45.00
+8,916.2%
-85.7%$2.11M$10.85M-0.03250Gap Down
High Trading Volume
NIVF
NewGenIvf Group
N/A$1.04
+1.0%
N/A-99.6%$543K$5.43M0.00N/AGap Down
High Trading Volume

Related Companies and Tools


This page (NASDAQ:ACON) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners